RT Journal
A1 Quill TE, Holloway R
T1 TIme-limited trials—reply
JF JAMA
JO JAMA
YR 2012
FD January 4
VO 307
IS 1
SP 33
OP 34
DO 10.1001/jama.2011.1955
UL http://dx.doi.org/10.1001/jama.2011.1955
AB 
In Reply: Although our Commentary focused exclusively on TLTs toward the very end of life, we agree with Drs Abernethy and Currow that the concept has much broader applicability. In fact, virtually all interventions with uncertain clinical effects on outcomes could be framed in these terms, in which the probability of success, markers of response, and associated time frames would be presented and agreed upon upfront (eg, nearly all palliative chemotherapy regimens, biological treatments for autoimmune disorders, and all major invasive interventions such as mechanical ventilation, renal dialysis, or feeding tubes).